pISSN 1226-6051
eISSN 2508-786X

Table. 4.

Table. 4.

Comparison of baseline characteristics between bisphosphonate monotherapy and calcitonin combination group for the treatment of mild and moderate to severe hypercalcemia

Mild (n=29)p-valueModerate-severe (n=63)p-value


BSP onlyBSP + calcitoninBSP onlyBSP + calcitonin
Sex, male12 (41.4%)9 (31.0%)0.3448 (12.7%)30 (47.6%)0.052

Age
 <65 years5 (17.2%)5 (17.2%)0.89312 (19.0%)31 (49.2%)0.568
 ≥65 years10 (34.5%)9 (31.0%)7 (11.1%)13 (20.6%)

GFR, ml/min/1.73 m2
 ≥301 (3.4%)2 (6.0%)0.5011 (1.6%)3 (4.8%)0.816
 <3014 (48.3%)12 (41.4%)18 (28.6%)4165.1%)

Cancer type
 Breast1 (3.4%)4 (13.8%)0.3343 (4.8%)6 (9.5%)0.751
 Lung7 (24.1%)5 (17.2%)5 (7.9%)11 17.5%)
 Kidney2 (6.9%)1 (3.4%)0 (0%)5 7.9%)
 Others5 (17.2%)4 (13.8%)11 (1 7.5%)22 (35.0%)

Cancer stage
 10 (0%)0 (0%)-0 (0%)1 1.6%)0.640
 20 (0%)0 (0%)0 (0%)1 (1.6%)
 30 (0%)0 (0%)0 (0%)0 (0%)
 415 (51.7%)14 (48.3%)19 (30.2%)42 (66.7%)

Bone metastasis8 (27.6%)34.5%)0.3163 (4.8%)17 (27.0%)0.074

Hypercalcemia history11 (37.9%)6 (20.7%)0.09614 (22.2%)18 28.6%)0.017

BSP, bisphosphonate; GFR, glomerular filtration rate

Korean J Clin Pharm 2019;29:166-72 https://doi.org/10.24304/kjcp.2019.29.3.166
© 2019 Korean J Clin Pharm